{
    "organizations": [],
    "uuid": "1213a48895a3759d69fce6c21e681cbf6576d211",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biolinerx-to-present-overall-survi/brief-biolinerx-to-present-overall-survival-data-at-eha-from-phase-2a-study-of-bl-8040-in-r-r-aml-patients-idUSFWN1SO0UV",
    "ord_in_thread": 0,
    "title": "BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - BioLine RX Ltd:\n* BIOLINERX TO PRESENT OVERALL SURVIVAL DATA AT EHA FROM PHASE 2A STUDY OF BL-8040 IN R/R AML PATIENTS\n* BIOLINE RX LTD - BL-8040 IN COMBINATION WITH CYTARABINE SHOWED SIGNIFICANTLY IMPROVED OVERALL SURVIVAL COMPARED TO HISTORICAL DATA IN TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-17T21:43:00.000+03:00",
    "crawled": "2018-05-18T19:40:46.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "bioline",
        "rx",
        "ltd",
        "biolinerx",
        "present",
        "overall",
        "survival",
        "data",
        "eha",
        "phase",
        "2a",
        "study",
        "aml",
        "patient",
        "bioline",
        "rx",
        "ltd",
        "combination",
        "cytarabine",
        "showed",
        "significantly",
        "improved",
        "overall",
        "survival",
        "compared",
        "historical",
        "data",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}